These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20652658)

  • 1. Telaprevir: a new hope in the treatment of chronic hepatitis C?
    Fowell AJ; Nash KL
    Adv Ther; 2010 Aug; 27(8):512-22. PubMed ID: 20652658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaprevir for the treatment of hepatitis C.
    Forestier N; Zeuzem S
    Expert Opin Pharmacother; 2012 Mar; 13(4):593-606. PubMed ID: 22332992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies for hepatitis C virus.
    Birerdinc A; Younossi ZM
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):535-44. PubMed ID: 20629602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telaprevir for chronic hepatitis C virus infection.
    Jesudian AB; Jacobson IM
    Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current therapies for chronic hepatitis C.
    Ferguson MC
    Pharmacotherapy; 2011 Jan; 31(1):92-111. PubMed ID: 21182362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C therapy in non-genotype 1 patients: the near future.
    Wartelle-Bladou C; Le Folgoc G; Bourlière M; Lecomte L
    J Viral Hepat; 2012 Aug; 19(8):525-36. PubMed ID: 22762136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in HCV therapy.
    Kronenberger B; Zeuzem S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.